ロード中...
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
Darolutamide is a novel androgen receptor (AR) antagonist with a distinct chemical structure compared to other AR antagonists and currently in clinical Phase 3 trials for prostate cancer. Using cell‐based transactivation assays, we demonstrate that darolutamide, its diastereomers and its main metabo...
保存先:
| 出版年: | Int J Cancer |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6766977/ https://ncbi.nlm.nih.gov/pubmed/30828788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32242 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|